300+ investors in your industry, stage, and region Get
Any industry
Video Games
Hospitality
EdTech
Restaurants
Google
Construction
Photography
Cryptocurrency
Clean Energy
Big Data
Email
Artificial Intelligence
Social Impact
SaaS
Energy
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
CleanTech
Travel
InsurTech
Oil and Gas
Film
Retail
Payments
Fitness
Marketplace
Organic Food
Machine Learning
Agriculture (AgTech)
Gaming
Blockchain
Facebook
B2B
Social Network
Medical Device
Education
Wellness
Sports
Automotive
eSports
Legal
Biotechnology
Software
Renewable Energy
Crowdfunding
Venture Capital
Social
Infrastructure
Beauty
Fashion
Climate
LGBT
Cannabis
Celebrity
Life Science
Food and Beverage
Publishing
Mobile Apps
Wine and Spirits
Music
Art
Real Estate
Sporting Goods
Manufacturing
FinTech
Finance
Digital Media
Social Media
Financial Services
Recruiting
Franchise
Non Profit
Internet
Mobile Advertising
Android
Proptech
Impact
Sustainability
Web3
Hardware
Medical
Biotech
Transportation
Enterprise
Community
Media (Entertainment)
Theatre
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
South Korea
Japan
Burkina Faso
Africa
Singapore
Brazil
LATAM
Gibraltar
Egypt
Taiwan
Zimbabwe
Tunisia
Sweden
Oceania
Hong Kong
Nigeria
Togo
Croatia
Iran
Guinea
Haiti
Kyrgyzstan
Norway
Lesotho
Isle of Man
Malawi
Nepal
Mexico
Liberia
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Romania
Zambia
Oman
Poland
Puerto Rico
Cameroon
Guernsey
Armenia
Colombia
China
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Australia
New Zealand
Morocco
Saudi Arabia
Sri Lanka
Jamaica
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Moldova
Botswana
Seychelles
Paraguay
Canada
South Africa
France
Denmark
Georgia
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Portugal
Rwanda
Sierra Leone
El Salvador
Senegal
Tanzania
Ireland
India
Germany
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Argentina
Europe
Qatar
Angola
Cyprus
Bangladesh
Barbados
Belgium
Jordan
Azerbaijan
Ethiopia
Bulgaria
Austria
Faroe Islands
Jersey
Bahrain
Ecuador
Estonia
Bahamas
Belize
Bolivia
Algeria
Italy
Belarus
Finland
Hungary
Grenada
Israel
Lithuania
Honduras
Iceland
Liechtenstein
Cambodia
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
Julianne Bruno, Angel Investor at Fairmount Funds Management

Julianne Bruno

Angel Investor @ Fairmount Funds Management

Boston, United States

Julianne Bruno is a post-ipo equity investor at Fairmount Funds Management in Boston focused on Health Care and Biotechnology. Julianne Bruno is the current Chief Operating Officer of CRISPR Therapeutics. She previously worked at McKinsey and Company as an Engagement Manager. Julianne Bruno attended The Wharton School.

Total investments:
1
Last investment:
Lead investor:
100%

Last updated:

Industries Julianne Bruno invests in

Health CareBiotechnologyHealth Diagnostics

Stages Julianne Bruno invests in

Post-IPO Equity

Countries Julianne Bruno invests in

Denmark

Contacts

TypeContactValidation
Work email
Personal email
Work phone
Personal phone
Socials

Sign up to unlock verified contacts

Unlock Contacts

Investment Focus

Industry

  • Health Care 1 (100%)
  • Biotechnology 1 (100%)
  • Health Diagnostics 1 (100%)

Investments

CompanyDescriptionRoundLinks
Galecto develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. GB0139 is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, in which there is high unmet medicalneed. Galecto was founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform. $284.9M / Post-IPO Equity / Nov 10, 2025

Co-Investors

Fairmount Funds Management

About Fairmount Funds Management

VC Fund · Philadelphia, United States

Fairmount Funds Management is a Philadelphia-based investment firm.

Fairmount Funds Management Contacts

NameEmailPhoneSocials
Peter Harwin
Peter Harwin Co-Founder and Managing Member

Sign up to unlock verified contacts

Unlock Contacts

See all 1 contact →

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Video Games
Hospitality
EdTech
Restaurants
Google
Construction
Photography
Cryptocurrency
Clean Energy
Big Data
Email
Artificial Intelligence
Social Impact
SaaS
Energy
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
CleanTech
Travel
InsurTech
Oil and Gas
Film
Retail
Payments
Fitness
Marketplace
Organic Food
Machine Learning
Agriculture (AgTech)
Gaming
Blockchain
Facebook
B2B
Social Network
Medical Device
Education
Wellness
Sports
Automotive
eSports
Legal
Biotechnology
Software
Renewable Energy
Crowdfunding
Venture Capital
Social
Infrastructure
Beauty
Fashion
Climate
LGBT
Cannabis
Celebrity
Life Science
Food and Beverage
Publishing
Mobile Apps
Wine and Spirits
Music
Art
Real Estate
Sporting Goods
Manufacturing
FinTech
Finance
Digital Media
Social Media
Financial Services
Recruiting
Franchise
Non Profit
Internet
Mobile Advertising
Android
Proptech
Impact
Sustainability
Web3
Hardware
Medical
Biotech
Transportation
Enterprise
Community
Media (Entertainment)
Theatre
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
South Korea
Japan
Burkina Faso
Africa
Singapore
Brazil
LATAM
Gibraltar
Egypt
Taiwan
Zimbabwe
Tunisia
Sweden
Oceania
Hong Kong
Nigeria
Togo
Croatia
Iran
Guinea
Haiti
Kyrgyzstan
Norway
Lesotho
Isle of Man
Malawi
Nepal
Mexico
Liberia
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Romania
Zambia
Oman
Poland
Puerto Rico
Cameroon
Guernsey
Armenia
Colombia
China
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Australia
New Zealand
Morocco
Saudi Arabia
Sri Lanka
Jamaica
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Moldova
Botswana
Seychelles
Paraguay
Canada
South Africa
France
Denmark
Georgia
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Portugal
Rwanda
Sierra Leone
El Salvador
Senegal
Tanzania
Ireland
India
Germany
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Argentina
Europe
Qatar
Angola
Cyprus
Bangladesh
Barbados
Belgium
Jordan
Azerbaijan
Ethiopia
Bulgaria
Austria
Faroe Islands
Jersey
Bahrain
Ecuador
Estonia
Bahamas
Belize
Bolivia
Algeria
Italy
Belarus
Finland
Hungary
Grenada
Israel
Lithuania
Honduras
Iceland
Liechtenstein
Cambodia
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Julianne Bruno invest in?

Julianne Bruno invests primarily in Health Care, Biotechnology and Health Diagnostics startups, most often at Post-IPO Equity stage. Most of the 1 investments tracked by Shizune back companies in Denmark. The Investment Focus section breaks down every industry, stage and country in the portfolio.

How do I contact Julianne Bruno?

Public channels for Julianne Bruno include LinkedIn, X (Twitter) and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

When did Julianne Bruno last invest?

The most recent investment recorded for Julianne Bruno closed in Nov 2025. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Julianne Bruno Julianne Bruno Find email